Journal of Pharmaceutical Care & Health Systems
Open Access

Pharmacokinetics, Growth and Development of Drug Prescribing Optimization

Anannaya Datta^{* *}Correspondence: Anannaya Datta, Department of Pharmachemistry, Acharya Nagarjuna University, Guntur, India, Email:

Author info »

Description

Pediatric clinical research is one of the research lines that have emerged due to its need and nature. This research area has definitely proved to be very interesting due to its characteristics, but it has also proved to be difficult for many researchers due to restrictions, especially the ethical concerns. These restrictions come about as it was clear that special groups, such as children, pregnant women, and the elderly, were involved in the final work during the phases of pharmacological research. When compared to the overall population, certain population groups inherently have less pharmacological therapy options.

The pharmaceutical industries, for their part, consider these special groups in their research works only when they are completely certain of the market for the sale of their products. As a result, the notation "without studies that demonstrate their trustworthy use appears on the medications that the specialists trying to treat for these patients are obliged to use.

The use of this drug is the sole responsibility of anybody who prescribes it is frequently found in most of the products. This is because there isn’t any research to back up the safe use of drugs in these particular groups.

Having becoming aware of the problem, the National Institute of Pediatrics (INP) in Mexico City formed a group of researchers led by Dr. Hugo Juarez Olguin to address it in the absence of alternative drug formulations for use in children. Juarez Olguin is a renowned specialist in the areas of clinical and experimenta pharmacology. He holds a doctorate in medical research, is a level 2 member of the National System of Researchers, and has over 30 years of experience as a professor of pharmacology at the UNAM Faculty of Medicine. With more than 20 years of experience and a wealth of experience in pediatric pharmacologica studies.

Dr. Juarez Olguin and his team of collaborators have been doing study to figure out the best and safe formulation for kids of many medicines that are only provided for adults. The work on the proper use of sildenafil in the treatment of pulmonary arteria hypertension and the development of the efficient pediatric antiarrhythmic propafenone pediatric suspended of which were awarded to him an invention out. Pharmacokinetic and pharmacodynamics study is one method for gaining knowledge that helps clinical-hospital decision-making. The notion to publish his research findings in the book "Optimization of Drug Prescribing in Children" arose from all these enormous works recently published by Nova Science Publishing House, in which he chronicled in black and white his years of invaluable knowledge that he puts at the service of readers seeking information on the proper management of medicines in the pediatric population.

The study of "Pharmacokinetics, Growth and Development" and "Main Diseases in Pediatrics Population," which showcase changes that occur from childhood until maturity and unquestionably affect children's basic organic functions and are directly and indirectly present in the pathologies that may affect this population group, are both remarkable and deserving of quotation in this synopsis. In the "Pharmacology for the Fetus and the Newborn" a comprehensive study of the biomedica aspects of early stages of life and how these differences make the infant's future was undertaken. Without sounding sensationalist, the chapters on "Suicidal Attempts by Drug Consumption in Children" and "Unintentional Poisoning with Drugs in the Pediatric Population" have brought attention since they were first published. These themes have been completely updated and now include a critical analysis of the causes, medical care approach, and recommendations when faced with these situations, as wel as the challenges that a physician may face in his professiona performance.